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The differentiation of effector CTLs requires 
that naive T cells undergo clonal expansion and 
reprogram their transcriptome to express the key 
cytolytic effector molecules that mediate the 
CD8+ T cell immune response. Moreover, a 
striking feature of CD8+ T cells is that they 
massively increase glucose uptake as they respond 
to an immune challenge and differentiate to 
cytolytic effectors (Fox et al., 2005; Maciver 
et al., 2008). They also switch from metaboliz-
ing glucose primarily through oxidative phos-
phorylation to using the glycolytic pathway. 
Glycolysis requires that T cells switch on and 
sustain expression of rate-limiting glycolytic 
enzymes such as hexokinase 2, phosphofructo-
kinase 1, pyruvate kinases, and lactate dehydrog-
enase and also requires that T cells can sustain 
high levels of glucose uptake by maintaining 
expression of the glucose transporter Glut1. 
In this context, it has been reported that rela-
tively high levels of exogenous glucose are 
required to sustain the transcriptional program 
of CTLs (Cham and Gajewski, 2005; Cham 
et al., 2008).
During CD8+ T cell differentiation, the gly-
colytic switch is initiated by antigen receptors 
and co-stimulatory molecules but is then sus-
tained by inflammatory cytokines such as IL-2. 
This cytokine controls the transcriptional pro-
gram that determines CD8+ T cell differentia-
tion and promotes effector CTL differentiation 
at the expense of memory cell formation (Kalia 
et al., 2010; Pipkin et al., 2010). In many cells, 
growth factors and cytokines control glucose 
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mTORC1 (mammalian target of rapamycin complex 1) controls transcriptional programs 
that determine CD8+ cytolytic T cell (CTL) fate. In some cell systems, mTORC1 couples 
phosphatidylinositol-3 kinase (PI3K) and Akt to the control of glucose uptake and glycoly-
sis. However, PI3K–Akt-independent mechanisms control glucose metabolism in CD8+  
T cells, and the role of mTORC1 has not been explored. The present study now demon-
strates that mTORC1 activity in CD8+ T cells is not dependent on PI3K or Akt but is critical 
to sustain glucose uptake and glycolysis in CD8+ T cells. We also show that PI3K- and Akt-
independent pathways mediated by mTORC1 regulate the expression of HIF1 (hypoxia-
inducible factor 1) transcription factor complex. This mTORC1–HIF1 pathway is required to 
sustain glucose metabolism and glycolysis in effector CTLs and strikingly functions to 
couple mTORC1 to a diverse transcriptional program that controls expression of glucose 
transporters, multiple rate-limiting glycolytic enzymes, cytolytic effector molecules, and 
essential chemokine and adhesion receptors that regulate T cell trafficking. These data 
reveal a fundamental mechanism linking nutrient and oxygen sensing to transcriptional 
control of CD8+ T cell differentiation.
© 2012 Finlay et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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RESULTS
mTORC1 regulates glucose uptake and glycolysis  
in TCR- and IL-2–stimulated CD8+ T cells
TCR triggering of naive CD8+ T cells with peptide–MHC 
complexes induced expression of the glucose transporter 
Glut1 and a concomitant increase in glucose uptake and lactate 
output (Fig. 1, A–C). TCR triggering also activated mTORC1 
activity (Fig. 1 D), as judged by assessing the impact of TCR 
ligation on phosphorylation of mTORC1 substrate sequences 
on S6K1 (T389 and S421/424) and the phosphorylation of 
the S6K1 substrate S6 ribosomal protein (S235/236). The in-
hibition of mTORC1 activity with rapamycin blocked TCR-
induced increases in Glut1 expression and glucose uptake and 
reduced lactate production (Fig. 1, E–G). TCR-primed CD8+ 
metabolism via signaling pathways controlled by phosphati-
dylinositol-3 kinase (PI3K) signals and the serine/threonine 
kinase Akt (also called protein kinase B). However, although 
PI3K and Akt direct the transcriptional program of CTLs, 
they are not required for the TCR-mediated initiation of 
glucose uptake nor are they required for IL-2 to sustain glucose 
uptake and glycolysis (Macintyre et al., 2011). Rather, this role is 
controlled by a PI3K-independent mechanism involving PDK1 
(phosphoinositide-dependent kinase 1; Macintyre et al., 2011).
In this context, in CD4 T cells, the serine kinase mTORC1 
(mammalian target of rapamycin complex 1) can control glucose 
metabolism via regulation of HIF1 (hypoxia-inducible factor 1) 
complexes (Shi et al., 2011). In CD8+ T cells, it has been 
recently reported that the initial glycolytic switch induced in 
response to antigen receptor triggering is mediated by c-myc 
and is independent of HIF1 (Wang et al., 2011). It thus remains 
to be determined whether the mTORC1–HIF1 pathway 
plays any role in controlling CD8+ T cell metabolism. Never-
theless, mTORC1 does play an essential role in CD8+ T cells 
to integrate inputs from nutrients, antigen, and cytokine 
receptors to control T cell differentiation (Powell and Delgoffe, 
2010). For example, inhibition of mTORC1 activity in effec-
tor CD8+ T cells can divert these cells to a memory fate 
(Araki et al., 2009). Moreover, mTORC1 signaling controls 
expression of cytolytic effector molecules in CTLs (Rao 
et al., 2010) and dictates the tissue-homing properties of these 
cells by regulating the expression of chemokine and adhesion 
receptors (Sinclair et al., 2008). However, the molecular 
mechanisms used by mTORC1 to control CD8+ T cell diff-
erentiation are not fully understood; neither are the signaling 
processes that activate mTORC1. Here it is pertinent that 
mTORC1 activity in CD8+ T cells is proposed to be con-
trolled by PI3K and Akt (Rao et al., 2010). If this model were 
correct, then the PI3K–Akt independence of glucose metab-
olism in CD8+ T cells would argue against a role for mTORC1 
in CD8+ T cell metabolism. The caveat is that models propos-
ing PI3K control of mTORC1 activity in T cells are based 
on experiments with the PI3K inhibitors wortmannin and 
LY294002, drugs which have very well-documented off-target 
effects; of most concern is that they can directly inhibit 
mTOR catalytic function (Brunn et al., 1996). The possibility 
thus remains that mTORC1 is a key regulator of glucose 
metabolism in CD8+ T cells but is activated via PI3K–Akt-
independent pathways.
Accordingly, the focus of the present study is the regulation 
and role of mTORC1 in CD8+ T cells. The data establish that 
PI3K- and Akt-independent mechanisms mediated by PDK1 
control mTORC1 activity in CD8+ T cells. They also expose 
that a PI3K- and Akt-independent pathway mediated by PDK1 
and mTORC1 controls expression of HIF1 transcriptional com-
plexes in CD8+ T cells. This mTORC1–HIF1 pathway is re-
quired to sustain glucose metabolism and glycolysis in effector 
CTLs and strikingly functions to couple mTORC1 to a diverse 
transcriptional program that controls expression of cytolytic 
effector molecules and essential chemokine and adhesion recep-
tors that regulate T cell trafficking.
Figure 1. mTORC1 regulates glucose uptake and glycolysis in TCR-
stimulated CD8+ T cells. (A) Immunoblot analysis of Glut1 expression in 
naive OTI CD8+ T cells ± TCR (SIINFEKL) stimulation for 20 h. (B and C) Naive 
P14-LCMV CD8+ T cells ± TCR (gp33-41/anti-CD28) stimulation were  
assayed for glucose uptake (B) and lactate production (C). (D) Immunoblot 
analysis of naive OTI CD8+ T cells ± TCR (SIINFEKL) stimulation for 20 h. 
mTORC1 activity was determined by analyzing the phosphorylation of 
target sequences on S6K1 (T389 and S241/242) and phosphorylation of 
the S6K1 substrate S6 ribosomal protein. PTEN was used as a loading 
control. (E–G) Immunoblot analysis (E) and analysis of glucose uptake  
(F) and lactate production (G) for naive P14-LCMV CD8+ T cells ± TCR 
(gp33-41/anti-CD28) stimulation with or without rapamycin for 20 h.  
For all panels, data are mean ± SEM or representative of at least three 
experiments. All metabolic assays were preformed in triplicate (**, P < 0.01; 
***, P < 0.001). Molecular mass is indicated in kilodaltons.
JEM Vol. 209, No. 13 
Article
2443
to TCR and IL-2 triggering, as judged by their ability to nor-
mally up-regulate expression of CD25, CD71, and CD44 and 
undergo blastogenesis (Fig. 3 F and not depicted). The deletion 
of HIF1 was confirmed by immunoblot analysis (Fig. 3 G). 
T cells cultured in IL-2 clonally expanded and differentiated 
to CTLs. One role for IL-2 is to sustain glucose uptake and 
glycolysis in TCR-primed T cells. CTLs cultured in IL-2 thus 
had high levels of Glut1 expression (Fig. 2 A), high levels of 
glucose uptake, and high levels of lactate output. The expres-
sion of Glut1 was lost when CTLs were deprived of IL-2 
(Fig. 2 B). Moreover, the removal of IL-2 caused CTLs to 
decrease glucose uptake and lactate output, i.e., glycolysis 
(Fig. 2, C and D). Strikingly, when CTLs were treated with 
rapamycin, they also decreased lactate output, which would 
be consistent with a model whereby rapamycin treatment 
inhibits glycolysis (Fig. 2 E). Consistent with such a model, 
rapamycin-treated T cells showed severely decreased glucose 
uptake, loss of Glut1 expression, and decreased expression 
of several essential glycolytic enzymes such as hexokinase 2, 
phosphofructokinase 1, pyruvate kinases, and lactate dehy-
drogenase (Fig. 2, F–H). mTORC1 thus integrates both TCR 
and IL-2 signaling to induce and sustain Glut1 expression and 
glucose uptake. mTORC1 also controls expression of key 
glycolytic enzymes in activated CD8+ T cells.
mTORC1 controls glucose uptake and glycolysis via HIF1
The expression of Glut1 can be controlled by the HIF1 and 
HIF1 (also known as ARNT or Aryl hydrocarbon receptor 
[AHR] nuclear translocator) complex (Semenza, 2010). Do 
CD8+ T cells express HIF1 complexes? Fig. 3 A addresses this 
issue and shows that TCR-triggered CD8+ T cells expressed 
both HIF1 and HIF1. Furthermore, as CD8 T cells differ-
entiated to CTLs, they increased and sustained high levels 
of HIF1 and HIF1 (Fig. 3 A) in a response that requires 
sustained IL-2 signaling and mTORC1 activity (Fig. 3 B). 
TCR-induced HIF1 expression in CD8+ T cells was thus 
dependent on mTORC1 activity (Fig. 3 C). Similarly, HIF1 
protein expression in IL-2–maintained CTLs was dependent 
on continuous mTORC1 activation (Fig. 3 D). The mTORC1 
dependence of HIF1 expression correlates with the require-
ment for sustained mTORC1 and cytokine signaling to control 
Glut1 expression and a glycolytic metabolism in CD8+ T cells 
(Figs. 1 and 2). In this respect, a previous study has implicated 
c-myc as a major regulator of glucose metabolism in T cells 
(Wang et al., 2011). However, the expression of c-myc in IL-
2–sustained CTLs was not dependent on mTORC1 (Fig. 3 E). 
The inhibition of mTORC1 with rapamycin thus inhibits 
Glut1 expression, glucose uptake, and glycolysis in CTLs 
independently of any effect on c-myc expression.
The HIF1 complex does not initiate but sustains  
glycolytic metabolism in CD8+ T cells
To explore a causal link between mTORC1, HIF1, and gly-
colysis, we deleted functional HIF1 transcriptional complexes 
in CD8+ T cells. In these experiments, mice with floxed 
HIF1 alleles were backcrossed to transgenic mice expressing 
Cre recombinase under the control of the CD4 promoter 
(CD4Cre). These mice produced a normal complement of 
peripheral / T cells in the thymus, lymph nodes, and spleen 
(not depicted). HIF1-null CD8+ T cells activated in response 
Figure 2. mTORC1 regulates glucose uptake and glycolysis in IL-2–
maintained CTLs. (A) Immunoblot analysis for Glut1 expression in naive 
OTI CD8+ T cells ± TCR (SIINFEKL) stimulation for 20 h and also mature OTI 
CTLs. The black line indicates that intervening lanes have been spliced out. 
(B) Immunoblot analysis for Glut1 expression in CTLs treated with or with-
out IL-2 for 20 h. 4EBP1 was used as a loading control. (C and D) Analysis of 
glucose uptake (C) and lactate production (D) in P14-LCMV CTLs treated 
with or without IL-2 for 20 h. (E and F) Analysis of lactate production  
(E) and glucose uptake (F) in P14-LCMV CTLs treated with or without rapa-
mycin for 20 h. (G) Immunoblot analysis for Glut1 expression in P14-LCMV 
CTLs treated with or without rapamycin for 20 h. 4EBP1 was used as a load-
ing control. (A–G) Data are mean ± SEM or representative of at least three 
experiments. All metabolic assays were preformed in triplicate (**, P < 0.01; 
***, P < 0.001). Molecular mass is indicated in kilodaltons. (H) SILAC-based 
proteomic analysis of P14-LCMV CTLs treated with and without rapamycin 
for 48 h. Shown is the relative expression of rate-limiting glycolytic en-
zymes (rapamycin/untreated). Data are mean ± SEM for three experiments 
and were analyzed by ANOVA (**, P < 0.01; ***, P < 0.001). CD8 was used 
as a control protein with unchanged expression.
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Figure 3. mTORC1 controls glucose uptake and glycolysis via HIF1. (A–D) Immunoblot analysis of HIF1 and HIF1 expression in naive P14-LCMV 
CD8+ T cells ± TCR (gp33-41/anti-CD28) stimulation for 20 h (A and C) and P14-LCMV CTLs (A, B, and D) treated with and without IL-2 (B) or rapamycin  
(C and D) for 20 h. Phospho-S6K1 and phospho-S6 were used as a measure of mTORC1 activity. (E) Immunoblot analysis of c-myc expression in CTLs 
treated with or without rapamycin for 20 h. Phospho-S6K1 and phospho-S6 were used as a measure of mTORC1 activity. (F) Flow cytometric analysis of 
HIF1WT/WT CD4Cre (WT) and HIF1flox/flox CD4Cre (HIF1/) CD8+ T cells after TCR (2c11) stimulation for 20 h. (G) Immunoblot analysis of WT and 
HIF1/ CTLs. (H and I) Analysis of glucose uptake (H) and lactate production (I) in WT and HIF1/ naive CD8+ T cells after TCR (2c11/anti-CD28) 
stimulation for 20 h. Glucose uptake in unstimulated WT naive T cells is also shown (uptake in unstimulated HIF1/ naive T cells is equivalent to WT; 
not depicted). (J–L) Analysis of glucose uptake (J), Glut1 expression (K), and lactate production (L) in WT versus HIF1/ CTLs. (M) A comparison of the 
transcriptional profile of HIF1 WT versus HIF1/ CTLs was performed by microarray. Shown here are KEGG pathway analysis of genes down-regulated in 
HIF1/ CTLs (top) and a heat map of the relative normalized expression of selected genes that are significantly different in expression in WT versus 
HIF1/ CTLs, as determined by microarray. For all panels, data are mean ± SEM or representative of at least three experiments. All metabolic assays were 
preformed in triplicate (**, P < 0.01; ***, P < 0.001). Molecular mass is indicated in kilodaltons. Dotted lines indicate that intervening lanes have been 
spliced out.
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of mTORC1 with rapamycin, which down-regulates HIF1 
complexes and severely impairs glucose metabolism and gly-
colysis in CD8+ T cells, does not block the proliferation of 
CTLs (Fig. 4 B).
A key role for mTORC1 in CD8+ T cells is to promote 
effector differentiation of CTLs by driving expression of 
genes encoding cytolytic effector molecules such as perforin, 
granzymes, and IFN-. We therefore interrogated the data to 
determine whether HIF1 transcriptional complexes mediate 
mTORC1 control of any of the key molecules that control 
CTL differentiation. It was thus striking that immune-activated 
HIF1-null CD8+ T cells had lost expression of perforin and 
multiple granzymes (Fig. 4 C). This was not a global block in 
CD8+ T cell differentiation as HIF1 complexes were not 
required for expression of other CD8 effector molecules such 
as IFN-, Fas ligand, or lymphotoxin (Fig. 4, C and D). More-
over, activated HIF1-null CD8+ T cells retained expression 
of the transcription factors T-bet and Blimp-1, which drive 
T cell differentiation (Fig. 4 E and Tables S1 and S2). The failure 
of immune-activated HIF1-null CD8+ T cells to express 
perforin was confirmed independently by quantitative PCR 
analysis of perforin mRNA levels and Western blot analysis 
of perforin protein expression (Fig. 4, F and G). Consistent 
with a role for mTORC1–HIF1 in controlling perforin ex-
pression, protein levels for perforin were also decreased after 
rapamycin treatment in WT CTLs (Fig. 4 G). We also assessed 
whether the expression of HIF1 complexes was rate limiting 
for perforin gene expression by examining the impact of 
hypoxia on the expression of perforin in WT CTLs. In these 
experiments, CTLs were switched from normoxic (21%) to 
hypoxic (1%) oxygen for 24 h. The switch to hypoxia strik-
ingly increased expression of HIF1 and also expression of 
Glut1, a direct HIF1 transcriptional target (Fig. 4 H). Impor-
tantly hypoxia also induced expression of perforin (Fig. 4 H). 
These data may explain earlier observations that CTLs cul-
tured under hypoxic conditions display increased cytotoxic 
function (Caldwell et al., 2001).
What is the mechanism for HIF1 control of perforin gene 
expression? HIF1 regulates the expression of Glut1 by direct 
binding to the Glut1 promoter. Similarly, HIF1-regulated gly-
colytic enzymes are direct HIF1 target genes. This raises the 
question of whether or not HIF1 regulation of perforin gene 
expression is direct or indirect. There was no evidence for 
HIF1-binding sites in the perforin promoter. Moreover, there 
was no change in the recruitment of RNA polymerase II 
(Pol II) to the transcription start site and distal exons of the 
perforin gene in HIF1-null CD8+ T cells (Fig. 4 I). Hence the 
loss of perforin mRNA in HIF1-null CD8+ T cells (Fig. 4 F) 
was not a consequence of the failure to recruit the appro-
priate transcription factors to the perforin locus. These data 
argue that the HIF1 effect on perforin expression is indirect. 
In this regard, one possibility we considered was that the loss 
of perforin expression might be an indirect consequence of 
failed glucose uptake. Here it is relevant that a previous study 
has shown that glucose deprivation prevents perforin expres-
sion in immune-activated CD8+ T cells (Cham et al., 2008). 
A previous study has suggested that the TCR-induced glyco-
lytic switch is regulated by c-myc and is not HIF1 dependent 
(Wang et al., 2011). The present data confirm this and show 
that TCR-induced glucose uptake and lactate output were 
normal in HIF1-null cells (Fig. 3, H and I). However, strik-
ingly, activated HIF1-null CD8+ T cells could not sustain 
high levels of glucose uptake as they differentiated to become 
cytolytic effectors in response to IL-2. HIF1-null immune-
activated CD8+ T cells maintained in the presence of IL-2 
thus had greatly decreased Glut1 expression and glucose uptake 
and produced significantly less lactate compared with control 
IL-2–maintained CTLs (Fig. 3, J–L). The ability of IL-2 to 
sustain glucose uptake and glycolysis is thus strictly depen-
dent on HIF1. In this context, HIF1 can complex with 
AHR. However, CTLs do not express high levels of the AHR, 
and there is little evidence of functional AHR signaling. More-
over, AHR-null CTLs have normal glucose uptake and lactate 
output (not depicted).
mTORC1 can regulate glycolysis by controlling expres-
sion of Glut1 and the expression of key glycolytic enzymes 
(Fig. 2, G and H). Is the role of HIF1 in CD8+ T cells 
restricted to control of Glut1 expression? To explore this issue, 
we used Affymetrix microarray analysis to transcriptionally 
profile HIF1-null CTLs. Approximately 11,517 annotated 
genes were expressed in CTLs, and the impact of HIF1 loss 
was a decrease in the expression of <5% of these genes and an 
increase in the expression of another 6%. The full list of genes 
changing in expression is detailed in Tables S1 and S2. We 
then used the functional annotation tools within DAVID 
Bioinformatics Resources 6.7 (Huang et al., 2009a,b) to per-
form gene annotation enrichment analysis and KEGG path-
way mapping of the significantly changed genes in the 
HIF1-null cells. This analysis indicated that one significant 
impact caused by the loss of HIF1 was down-regulation of 
multiple genes encoding proteins that control glycolysis and 
pyruvate metabolism (Fig. 3 M). HIF1-null cells thus cannot 
sustain expression of key rate-limiting glycolytic enzymes: 
hexokinase 2, pyruvate kinase 2, phosphofructokinase, and 
lactate dehydrogenase. The ability of HIF1 complexes to sus-
tain the T cell glycolytic switch thus extends beyond a simple 
model of HIF1 regulation of Glut1 and glucose uptake.
The HIF1 complex regulates the CD8+ T cell transcriptional 
program but is not essential for T cell proliferation
The massive up-regulation of glucose metabolism and the 
switch to glycolysis under normoxia that accompanies the 
immune activation of CD8 T cells are thought to be essential 
to meet the metabolic demands caused by the rapid prolifera-
tion of clonally expanding CD8+ T cells. However, CD8+  
T cells deleted of HIF1 transcriptional complexes proliferated 
and clonally expanded normally (Fig. 4 A). Moreover, tran-
scriptional profiling of HIF1-null CTLs using Affymetrix 
microarray analysis did not reveal any negative impact of HIF1 
deletion on cell cycle progression, cell survival, or mitosis 
(Tables S1 and S2). The failure to see proliferative defects in 
HIF1-null T cells is consistent with observations that inhibition 
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immune-activated CTLs (Fig. 5 A). Moreover, the expression 
of the gene encoding the cell adhesion molecule CD62L 
(L-selectin) was increased in HIF1-null cells (Fig. 5, A and B). 
Immune-activated CD8+ T cells down-regulate CD62L gene 
transcription, and thus CTLs normally express low levels of 
this adhesion molecule (Fig. 5, B and C; Sinclair et al., 2008). 
However, CD62L mRNA and protein levels were high in 
activated HIF1-null CD8+ T cells (Fig. 5, B and C). CCR7 
is a chemokine receptor that coordinates the migration of 
T cells into lymph nodes and is normally down-regulated in 
CTLs. PCR analysis confirmed the microarray data: immune-
activated HIF1-null T cells retained high levels of CCR7 
mRNA compared with normal CTLs (Fig. 5 D).
CD62L and CCR7 are expressed at high levels in naive 
and memory T cells and are essential for lymphocyte trans-
migration from the blood into secondary lymphoid tissue. 
CD62L and CCR7 loss is thus part of the program that redi-
rects effector T cell trafficking away from lymphoid tissue 
toward sites of inflammation. In this respect, inhibition of 
The present data (Fig. 4 J) show that CTLs maintained in 
2 mM glucose express substantially lower levels of perforin 
compared with the control cells maintained in 10 mM glucose. 
This could explain why an early study noted that glucose 
deprivation can limit the cytolytic function of effector CTLs 
(MacDonald and Koch, 1977).
HIF1 regulation of chemokines and chemokine receptors
One unexpected outcome from the microarray experiment 
came from the bioinformatic pathway analysis of the genes 
whose expression was increased in HIF1-null T cells. This 
analysis indicated that immune-activated HIF1-null CD8+  
T cells up-regulated the expression of genes involved in cyto-
kine/cytokine receptor interactions (Fig. 5 A). Closer data 
interrogation revealed that these HIF1-regulated genes enco-
ded chemokines, chemokine receptors, and adhesion mole-
cules. For example, loss of HIF1 transcriptional complexes 
increased expression of mRNA encoding the chemokine 
receptors S1P1, CXCR4, CXCR3, CCR5, and CCR7 in 
Figure 4. The HIF1 complex regulates the CD8+  
T cell transcriptional program but is not essential 
for T cell proliferation. (A and B) Proliferation analysis 
of WT and HIF1/ CTLs (A) and P14-LCMV CTLs treated 
with and without rapamycin (B). Cells were seeded at  
0.3 × 106/ml, and CTL numbers were counted after 24 h.  
Data are mean ± SEM of five experiments. (C) Heat map 
showing the relative normalized expression of selected 
genes that are significantly different in expression in  
WT versus HIF1/ CTLs, as determined by microarray.  
(D) Real-time PCR analysis of IFN- expression in WT 
and HIF1/ CTLs. Data are mean ± SEM of three experi-
ments in triplicate. (E) Immunoblot analysis of T-bet and 
Blimp1 expression in WT and HIF1/ CTLs. Data are 
representative of two experiments. (F) Real-time PCR 
analysis of Perforin mRNA expression in WT and HIF1/ 
CTLs. Data are mean ± SEM of three experiments in trip-
licate (**, P < 0.01). (G) Immunoblot analysis of Perforin 
protein expression in WT and HIF1/ CTLs (top) and 
P14-LCMV CTLs treated ± rapamycin for 20 h (bottom). 
Data are representative of at least three experiments.  
(H) IL-2–maintained CTLs were placed in either hypoxic 
(1%) or normoxic (20%) oxygen for 24 h before being 
subjected to immunoblot analysis for HIF1, Glut1, and 
perforin expression. Data are representative of three 
experiments. (I) ChIP was performed with anti–Pol II, and 
the changes in Pol II binding to the Perforin transcription 
start site and the second exon were quantified by real-
time PCR. Data were normalized to input DNA amounts 
and plotted as fold over the values for Pol II binding to 
the HPRT proximal promoter. Data are mean ± SEM of 
three experiments performed in duplicate. (J) P14-LCMV 
T cells were activated for 2 d with gp33-41 and then 
cultured for a further 4 d with IL-2 in different glucose 
concentrations. Cells were then subjected to immunoblot 
analysis for perforin expression. Data are representative 
of two experiments. Molecular mass is indicated in kilo-
daltons. Black lines (solid or dotted) indicate that inter-
vening lanes have been spliced out.
JEM Vol. 209, No. 13 
Article
2447
T cells not only retained expression of the secondary lym-
phoid organ-homing receptors but also increased expression 
of inflammatory chemokine receptors such as CXCR3 and 
CCR5 (Fig. 5 A). These pleiotropic effects make it more dif-
ficult to predict the impact of HIF1 loss on T cell trafficking 
in vivo. Accordingly, the in vivo lymph node–homing ability 
of activated control or HIF1-null CD8+ T cells was com-
pared. Strikingly, activated CD8+ T cells that lacked HIF1-
mediated transcription retained the capacity to home to 
secondary lymphoid organs and accumulated in the lymph 
nodes (Fig. 5 E). There is therefore a dominant requirement 
for HIF1 transcriptional complexes for the normal program-
ming of effector CD8+ T cell trafficking. Is HIF1 regulation 
of CD62L gene expression direct, or is the impact of HIF1 on 
CD62L expression an indirect consequence of the inability 
of HIF1-null cells to maintain glucose uptake? The experi-
ment in Fig. 5 F addresses this issue and shows that CD8+  
T cells stimulated by antigen and IL-2 in culture media with 
low glucose levels fail to down-regulate CD62L expression.
PI3K- and Akt-independent control of mTORC1  
activity and HIF1 expression in CD8+ T cells
The insight that HIF1 transcription factor complexes mediate 
mTORC1 control of the expression of CD62L, CCR7, 
and S1P1 raises a question. How does the mTORC1–HIF1 
pathway that controls T cell trafficking connect to a well-
documented PI3K–Akt–Foxo pathway that also controls the 
expression of these key trafficking molecules? The retention 
of high levels of CCR7 and CD62L expression by immune-
activated HIF1-null CD8+ T cells thus phenocopies the 
impact of inhibiting PI3K–Akt signaling in activated CD8+  
T cells (Sinclair et al., 2008; Waugh et al., 2009; Macintyre 
et al., 2011). PI3K–Akt control of CD62L, CCR7, and S1P1 
expression reflects that the expression of these molecules is 
regulated by the Foxo1 transcription factor (Fabre et al., 2008; 
Kerdiles et al., 2009). Foxo1 is inactivated by Akt, which 
phosphorylates Foxo1, resulting in its nuclear exclusion and 
retention in the cytosol. Akt inhibition results in dephosphor-
ylation of Foxo1 and restores its nuclear location and tran-
scriptional activity and restores expression of CD62L and 
CCR7 in CTLs (Waugh et al., 2009; Macintyre et al., 2011).
Accordingly, a key question is whether mTORC1 and/or 
expression of HIF1 complexes regulate Akt activity and Foxo 
phosphorylation in T cells. It is also pertinent to question 
whether PI3K and Akt control mTORC1 activity in CD8+  
T cells. Lymphocyte signaling models frequently position 
PI3K–Akt signaling as an upstream obligatory regulator of 
mTORC1 activity. However, the present results showing that 
mTORC1 controls glucose metabolism in T cells are incon-
sistent with these models because they are discrepant with 
observations that PI3K and Akt do not control glucose uptake 
in CD8+ T cells (Macintyre et al., 2011). Moreover, the present 
data herein show that the mTORC1–HIF1 pathway controls 
expression of the rate-limiting glycolytic enzymes (Figs. 2 H 
and 3 M). In contrast, microarray analysis of Akt-regulated 
mTORC1 with rapamycin can restore expression of CD62L 
and CCR7 in effector T cells and reprogram their trafficking 
such that they regain the ability to home to secondary lym-
phoid organs (Sinclair et al., 2008). The retention of CD62L 
and CCR7 on immune-activated HIF1-null CD8+ T cells 
thus raises the possibility that these cells may retain the migra-
tory properties of naive T cells and preferentially home to 
secondary lymphoid tissues. However, HIF1-null CD8+  
Figure 5. HIF1 regulation of chemokines and chemokine receptors. 
(A) A comparison of the transcriptional profile of WT versus HIF1/ CTLs 
was performed by microarray. Shown here are KEGG pathway analysis of 
genes up-regulated in HIF1/ CTLs (top) and a heat map showing the 
relative normalized expression of selected genes that are significantly 
different in expression in WT versus HIF1/ CTLs, as determined by  
microarray. (B) Real-time PCR analysis of CD62L expression in WT and 
HIF1/ CTLs. (C) Analysis of CD62L surface expression on WT and HIF1/ 
CTLs by flow cytometry. (D) Real-time PCR analysis of CCR7 expression in 
WT and HIF1/ CTLs. (E) WT and HIF1/ CTLs were labeled with CFSE or 
CellTracker orange (CMTMR) and mixed at a ratio of 1:1 before being in-
jected into C57BL/6 host mice. Values indicate recovery of WT or HIF1/ 
cells as a percentage of the total recovered transferred cells from the 
blood and lymph nodes 4 h after transfer. Each dot indicates a mouse; 
horizontal bars indicate mean. (F) P14 T cells were activated for 2 d with 
cognate peptide and then cultured for a further 4 d with IL-2 in different 
glucose concentrations. Cells were then analyzed for the surface expres-
sion of CD62L by flow cytometry. In B and D, mean ± SEM of three  
experiments performed in triplicate is shown; in C and F, data are  
representative of at least three experiments (*, P < 0.05; **, P < 0.01).
2448 mTOR/HIF1 controls CTL metabolism and migration | Finlay et al.
inhibitor, Akti1/2, or a p110 inhibitor, IC87114, potently 
inhibited Akt activity in CTLs as judged by the loss of phos-
phorylated Akt on T308 and S473 and inhibition of the phos-
phorylation of the Akt substrates, Foxo transcription factors 
(Fig. 7, A and B). However, neither Akti1/2 nor IC87114 
prevented mTORC1 activity in CD8+ T cells as neither com-
pound blocked the phosphorylation of mTORC1 substrates 
S6K1 and 4EBP1 or S6 phosphorylation in CTLs (Fig. 7 A). 
Moreover, CTLs that had WT PI3K p110 catalytic subunits 
substituted with a catalytically inactive mutant (p110D910A) 
did not activate Akt in response to IL-2 but showed normal 
rapamycin-sensitive phosphorylation of S6K1 and S6 (Fig. 7 C). 
Further evidence that mTORC1 activity is independent of 
PI3K and Akt is that the expression of HIF1 was not regu-
lated by Akt and PI3K inhibitors (Fig. 7 D). These data reveal 
that PI3K–Akt activity is dispensable for mTORC1 activity 
and HIF1 expression in CTLs.
If mTORC1 activity is not mediated by Akt, then what is 
the alternative pathway? One candidate is the serine/threonine 
genes in T cells failed to find any evidence that Akt controlled 
glucose metabolism or glycolysis (Macintyre et al., 2011).
To explore the links between PI3K, Akt, mTORC1, and 
HIF1, we addressed two questions. Do mTORC1 and HIF1 
regulate Akt activity and Foxo phosphorylation? Is PI3K and 
Akt activity required for mTORC1 activation and HIF1 
expression? In the context of the first question, long-term 
inhibition of mTORC1 can destabilize mTORC2 complexes 
in some cell systems and suppress Akt function (Sarbassov 
et al., 2006). Indeed, rapamycin treatment of CD4 T cells 
activated with CD3 and CD28 antibodies does diminish Akt 
S473 phosphorylation, although the impact of this on Akt 
activity has not been fully assessed (Lee et al., 2010; Delgoffe 
et al., 2011). If this were true in CTLs, then long-term treat-
ment of T cells with rapamycin would result in the loss of 
Foxo phosphorylation and cause cells to regain Foxo tran-
scriptional activity and thus CD62L and CCR7 expression. 
We therefore examined the impact of long-term inhibition 
of mTORC1 with rapamycin on Foxo phosphorylation 
and localization in CTLs. We also assessed Akt–Foxo and 
mTORC1 signaling in IL-2–maintained HIF1-null T cells to 
assess whether loss of HIF1 complexes compromised Foxo 
phosphorylation/inactivation. Fig. 6 (A and B) shows that 
inhibition of Akt decreased Foxo phosphorylation (Fig. 6 A) 
and restored nuclear localization of Foxos in CTLs (Fig. 6 B). 
In contrast, Akt remained active, i.e., phosphorylated on T308 
and S473, and Foxos remained highly phosphorylated and 
excluded from the nucleus of rapamycin-treated CTLs (Fig. 6, 
A and B). Additionally, Akt phosphorylation (T308) and the 
phosphorylation of Foxo transcription factors on Akt sub-
strate sites (T24/32) were unaffected in HIF1-null CTLs, 
demonstrating that Akt signaling is not altered by HIF1 dele-
tion (Fig. 6 C). It was also evident that the phosphorylation 
of mTORC1 substrates S6K1 (p70 S6-kinase 1) and 4EBP1 
(eIF4E-binding protein 1), on T389 and S65, respectively, 
and downstream signaling to S6 ribosomal protein (an S6K1 
substrate) were normal in HIF1-null CD8+ T cells (Fig. 6 C). 
Therefore, mTORC1 and HIF1 regulate the expression of 
CD62L and CCR7 and T cell trafficking but do not control 
Akt–Foxo phosphorylation and localization.
What about the second question? Are PI3K and Akt 
activity required for mTORC1 activation and HIF1 expres-
sion in CD8+ T cells? To address this issue, we used comple-
mentary genetic and pharmacological strategies to block PI3K 
and Akt and then monitored the impact of these perturba-
tions on mTORC1 activity by assessing the phosphoryla-
tion of mTORC1 substrate sequences on S6K1 (T389 and 
S421/424) and 4EBP1 (S35/47) and the phosphorylation 
of the S6K1 substrate S6 ribosomal protein (S235/236). The 
data show that IL-2–maintained CTLs contain high levels 
of active Akt phosphorylated on threonine 308 and high 
levels of mTORC1 signaling (Fig. 7 A). mTORC1 inhibition 
with rapamycin abolished the phosphorylation of S6K1 on 
T389 and S421/424 and blocked S6 phosphorylation. In 
CD8+ T cells, Akt is activated via a PI3K complex containing 
the p110 catalytic subunit (Macintyre et al., 2011). The Akt 
Figure 6. mTORC1 and HIF1 do not regulate Akt activity or Foxo 
phosphorylation. (A) Immunoblot analysis of phosphorylated AKT and 
Foxos in P14-LCMV CTLs treated with and without Akti1/2 or rapamycin 
for 24 h. (B) P14-LCMV CTLs were treated with and without rapamycin or 
Akti1/2 for 24 h and subjected to nuclear/cytoplasmic fractionation  
before immunoblot analysis for Foxo1 and Foxo3a expression. Purity of 
cytoplasmic and nuclear fractions was confirmed by IB and Smc1  
expression. (C) Immunoblot analysis of WT or HIF1/ CTLs for Akt–Foxo 
and mTORC1 signaling. HIF1/ CTLs were treated with rapamycin as a 
negative control for mTORC1 activity. For all panels, data are representa-
tive of at least three experiments. Molecular mass is indicated in kilodal-
tons. Dotted lines indicate that intervening lanes have been spliced out.
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these results show that in CD8+ T cells, mTORC1 activity 
and HIF1 protein expression are controlled by a PI3K– 
Akt-independent pathway mediated by PDK1.
DISCUSSION
The present study explores the molecular pathways that 
mediate mTORC1 control of effector CD8+ T cell differen-
tiation. A key finding was that mTORC1 activity is required 
for immune-activated CD8+ T cells to sustain high rates of 
glucose uptake. mTORC1 activity is also necessary for CD8+ 
T cells to initiate and sustain a switch to a glycolytic metabo-
lism. One way in which mTORC1 controls glucose uptake 
in CD8+ T cells is by controlling expression of the glucose 
transporter Glut1. CD8+ T cells also show mTORC1 depen-
dence for the expression of hexokinase 2, a key enzyme which 
phosphorylates glucose to produce glucose-6-phosphate, 
kinase PDK1 because this is known to be an essential regula-
tor of glucose metabolism in CD8+ T cells (Macintyre et al., 
2011). We therefore examined whether PDK1 regulates 
mTORC1 activity and HIF1 expression in activated CD8+  
T cells. For these experiments, mice expressing floxed PDK1 
alleles were backcrossed with mice that express a tamoxi-
fen-regulated Cre recombinase (Macintyre et al., 2011). 
PDK1flox/flox TamoxCre CTLs were generated and treated with 
4-hydroxytamoxifen (4OHT) to delete floxed PDK1 alleles. 
PDK1 deletion was confirmed by analysis of PDK1 protein 
expression and by the loss of RSK phosphorylation on its 
PDK1 target site (S227; Fig. 7 E). Importantly, deletion 
of PDK1 in CTLs prevented the phosphorylation of the 
mTORC1 substrates S6K1 and 4EBP1 on mTORC1 target 
residues (Fig. 7 F). PDK1 loss also resulted in loss of expression 
of HIF1 and the HIF1 target Glut1 (Fig. 7 G). Together 
Figure 7. PI3K and Akt do not regulate mTORC1 activity. (A and B) CTLs were cultured in the presence or absence of Akti1/2, IC87114, rapamycin, 
or LY294002 for 60 min (A and B) or 24 h (A) and subjected to immunoblot analysis with the indicated antibodies. (C) CTLs generated from WT or 
p110D910A mice were subjected to immunoblot analysis with or without rapamycin treatment (30 min). Data are representative of two experiments.  
(D) CTLs were cultured in the presence or absence of Akti1/2, IC87114, or rapamycin for 24 h and subjected to immunoblot analysis with the indicated 
antibodies. (E–G) CTLs generated from PDK1flox/flox TamoxCre (PDK1Flox) and PDK1WT/WT TamoxCre (WT) mice were treated ± 4OHT for 3 d to delete PDK1 
and subjected to immunoblot analysis. For, A, B, and D–G, data are representative of at least three experiments. Molecular mass is indicated in kilodaltons.
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T cells thus affords the insight that mTORC1 regulation of 
HIF1 controls expression of a subset of CTL effector mole-
cules and controls CD8+ T cell trafficking. These findings 
reveal a fundamental mechanism linking nutrient sensing and 
transcriptional control of CD8+ T cell differentiation. Although 
the HIF1 complex evolved to function as a metabolic sensor 
of cellular oxygen levels, the present study reveals a novel role 
for the HIF1 complex in coupling mTORC1 to the control 
of T cell differentiation.
How does this mTORC1–HIF1 pathway coordinate 
with other signaling pathways that control CD8+ T cell dif-
ferentiation? A particular issue is that models of lymphocyte 
signal transduction invariably link mTORC1 to PI3K–Akt 
signaling. As discussed, the biochemical experiments that 
initially proposed this model are flawed because the pharma-
cological tools used have numerous off-target effects. Never-
theless, the concept of a linear model of PI3K–Akt–mTORC1 
signaling is still compelling because the phenotypes of T cells 
activated in the presence of PI3K–Akt or mTORC1 inhibitors 
show similarities. For example, the expression of perforin is 
positively regulated by both Akt (Macintyre et al., 2011) and 
mTORC1 (Fig. 4 G), and the expression of CD62L, CCR7, 
and S1P1 is negatively regulated by both Akt and mTORC1 
(Sinclair et al., 2008; Macintyre et al., 2011). In a linear model, 
it would be assumed that PI3K and Akt activity are required 
for mTORC1 activation. Moreover, there are models propos-
ing mTORC1 control of Akt activity. This latter idea stems 
from experiments showing that in some cell systems, pro-
longed inhibition of mTORC1 with rapamycin can disrupt 
the mTORC2 serine/threonine kinase complex (Sarbassov 
et al., 2006). mTORC2 phosphorylates Akt on S473, and it 
has been shown that prolonged rapamycin treatment reduces 
Akt S473 phosphorylation in CD4 T cells activated with CD3 
and CD28 antibodies (Lee et al., 2010; Delgoffe et al., 2011). 
It is frequently assumed that loss of Akt S473 phosphorylation 
will block Akt catalytic activity. However, the key rate-limiting 
phosphorylation on Akt is the PDK1-mediated phosphoryla-
tion of T308, and the impact of the reduced Akt S473 phos-
phorylation on Akt catalytic function in CD4 T cells has not 
been studied in detail. Moreover, does rapamycin treatment 
actually disrupt mTORC2 complexes in all T cells? The cur-
rent study addresses these issues and shows unequivocally that 
PI3K and Akt activity are not essential for mTORC1 activa-
tion or for HIF1 expression in CD8+ T cells. Moreover, rapa-
mycin treatment, even long term, does not prevent Akt 
phosphorylation or activity, as judged by the normal phos-
phorylation and nuclear exclusion of the Foxo transcription 
factors in rapamycin-treated T cells. There is a well-documented 
Akt–Foxo-mediated pathway to control T cell trafficking in 
CD8+ T cells, but the mTORC1–HIF1 pathway that controls 
T cell trafficking described herein is independent of Akt and 
Foxos. The present study thus indicates that PI3K–Akt and 
mTORC1 signaling are not linked in a linear pathway. These 
molecules are activated independently but converge to control 
the expression of key molecules required for effector CTL 
function. An essential requirement for these two independent 
an essential intermediate in most pathways for glucose 
metabolism. Importantly, mTORC1 controls expression of 
key rate-limiting glycolytic enzymes in CD8+ T cells such as 
phosphofructokinase 1, lactate dehydrogenase, and pyruvate 
kinase M2.
This ability of mTORC1 to coordinate and sustain 
expression of glucose transporters and essential glycolytic 
enzymes during CD8+ T cell differentiation stems from its 
ability to control expression of the HIF1 transcription factor 
complex. The initial increase in glucose uptake and switch 
to glycolysis that immediately follows TCR engagement is 
not HIF1 dependent. However, HIF1 is essential for antigen-
primed T cells to sustain high levels of glucose uptake and 
glycolytic enzyme expression as they differentiate to cytolytic 
effector cells. In this respect, CTL differentiation is controlled 
by the strength and duration of signaling by inflammatory 
cytokines such as IL-2 (Kalia et al., 2010; Pipkin et al., 2010). 
The present data now show that the ability of IL-2 to sus-
tain high levels of glucose uptake and maintain a glycolytic 
metabolism is dependent on mTORC1 induction of HIF1 
complexes. However, it was notable that the inhibition of 
mTORC1 in IL-2–maintained CTLs suppressed glucose 
uptake and lactate output without having any impact on the 
expression of c-myc (Fig. 3 E). This is relevant because it 
has been shown recently that c-myc is required for the 
initial TCR-induced glycolytic switch in naive T cells (Wang 
et al., 2011). The present data thus reveal that c-myc ex-
pression alone is not sufficient to maintain glucose uptake 
and glycolysis in CD8+ T cells. Moreover the coordination 
of c-myc and HIF1 expression must be required for T cells 
to sustain glucose uptake and glycolysis during CD8+  
T cell differentiation.
The ability of HIF1 to link mTORC1 to the control of 
glucose metabolism in CD8+ T cells made us question 
whether any other actions of mTORC1 in CD8+ T cell are 
directed by the HIF1 pathway. In particular, it is well docu-
mented that mTORC1 activity is required for expression 
of CTL effector molecules and for effector CD8+ T cells to 
switch off expression of the chemokine receptors and adhe-
sion molecules that direct naive and memory T cell entry 
and egress from secondary lymphoid tissues. For example, 
mTORC1 signaling causes down-regulation of the adhesion 
molecule CD62L and the chemokine receptors CCR7 and 
S1P1 (Sinclair et al., 2008). In this regard, the phenotype of 
the immune-activated HIF1-null T cells is intriguing. They 
have many features of effector CD8+ T cells such as normal 
IFN- production and expression of effector molecules such 
as Fas ligand and lymphotoxin. Also, they are normal in cell 
size and can rapidly proliferate. However, the HIF1-null cells 
lack perforin and granzyme expression. Moreover, although 
they acquire the expression of effector CTL chemokine 
receptors such as CXCR3 and CCR5, they retain the expres-
sion of naive T cell lymph node–homing receptors CD62L, 
CCR7, and S1P1. They also retain the secondary lymphoid 
tissue migratory program of naive T cells in vivo. The tran-
scriptional profiling of HIF1-null immune-activated CD8+ 
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P-40, 1 mM PMSF, 1 mM Na3VO4, and 1 mM DTT) and centrifuged at 4°C 
for 1 min at 10,000 g. Cytosolic fractions were removed, and nuclear mem-
brane fractions were suspended in the aforementioned Tris lysis buffer. 
Immunoblot analysis of IB and Smc1 was used to confirm the purity 
of cytoplasmic and nuclear fractions, respectively.
Glucose uptake. 106 cells were suspended in 400 µl glucose-free media 
containing 0.5 µCi/ml 2-deoxy-d-[1-3H]glucose ([3H] 2-DG; GE Health-
care) and incubated for 3 (CTLs) or 10 min (TCR-simulated CD8+ T cells). 
Cells were pelleted, washed, and lysed overnight with 200 µl of 1 M NaOH, 
and the incorporated 3H radioactivity was quantified via liquid scintillation 
counting. Measurements were performed in triplicates per condition.
Quantitative real-time PCR. RNA was extracted using the RNeasy 
RNA purification mini kit (QIAGEN) according to the manufacturer’s pro-
tocol. Purified RNA was reverse transcribed using the qScript cDNA syn-
thesis kit (Quanta). Real-time PCR was performed in triplicates in 96-well 
plates using iQ SYBR Green–based detection on an iCycler (Bio-Rad Labo-
ratories). For the analysis of mRNA levels, the derived values were averaged 
and normalized to HPRT mRNA levels.
Primers. Primers used are as follows: HPRT forward, 5-TGATCAGTCA-
ACGGGGGACA-3; HPRT reverse, 5-TTCGAGAGGTCCTTTTCA-
CCA-3; CD62L forward, 5-ACGGGCCCCAGTGTCAGTATGTG-3; 
CD62L reverse, 5-TGAGAAATGCCAGCCCCGAGAA-3; CCR7 forward, 
5-CAGCCTTCCTGTGTGATTTCTACA-3; CCR7 reverse, 5-ACC-
ACCAGCACGTTTTTCCT-3; Perforin forward, 5-CGTCTTGGTGG-
GACTTCAG-3; Perforin reverse, 5-GCATTCTGACCGAGGGCAG-3; 
IFN- forward, 5-TTACTGCCACGGCACAGTC-3; and IFN- reverse, 
5-AGATAATCTGGCTCTGGCTCTGCGG-3.
Lactate measurement. 2 × 106/ml CTLs were cultured for 4 h in RPMI 
1640 containing 10% dialyzed fetal calf serum, and then the cells were spun 
and the supernatants were collected. Lactate concentration in the supernatant 
was quantified using an LDH (lactate dehydrogenase)-based enzyme assay, 
monitoring the emergence of NADH through increased absorption at 340 nm 
(the reaction contained 320 mM glycine, 320 mM hydrazine, 2.4 mM NAD+, 
and 3 U/ml LDH). A standard curve was generated, and the concentration of 
lactate in the supernatant added to this reaction was calculated.
Adoptive transfer. CTLs were generated from the spleens of HIF1flox/flox 
CD4Cre mice or HIF1flox/flox mice (as described in Cell culture but with 
4 d in IL-2). Cells were then labeled with either CFSE (Invitrogen) or Cell-
Tracker Orange (CMTMR; Invitrogen) for 15 min at 37°C, washed, mixed 
at 1:1 ratio, and suspended in sterile PBS. 5 × 106 mixed cells were injected 
into the tail vein of C57BL/6 host mice. After 4 h, the mice were sacrificed, 
and lymph nodes, spleen, and blood were analyzed and the ratio of CFSE- and 
CMTMR-labeled T cells quantified. Values indicate recovery of HIF1flox/flox 
CD4Cre cells versus HIF1flox/flox cells as a percentage of the total recovered 
transferred cells.
Chromatin immunoprecipitation (ChIP). Real-time PCR-based ChIP 
analysis to measure Pol II binding to the Perforin locus was performed as 
described previously (Cruz-Guilloty et al., 2009) with minor modifications. 
In brief, chromatin was immune precipitated with anti–Pol II (Santa Cruz 
Biotechnology, Inc.) or normal rabbit IgG (Cell Signaling Technology) 
from 5 × 106 cells in the presence of 0.2 mg/ml BSA. ChIP-grade protein 
G magnetic beads (Cell Signaling Technology) were used to collect the 
immune complexes. Chromatin was purified via a NucleoSpin Extract II kit 
(Macherey-Nagel) and resuspended in TE buffer. Real-time PCR was 
performed in an iQ5 (Bio-Rad Laboratories) with Perfecta SYBR green 
FastMix for iQ (Quanta BioSciences). Primers are as follows: Perforin TSS 
forward, 5-CAGGGCAGGAAGTAGTAATGATATG-3; Perforin TSS 
reverse, 5-CTTCCTCCTCCTTACCTGAAGTC-3; Perforin Exon2 
forward, 5-CCAGAGTTTATGACTACTGTG-3; and Perforin Exon2 
reverse, 5-GTGCTTCTGCTTGCATTCTG-3.
signaling pathways to control T cell differentiation highlights 
the importance of integrating lymphocyte signal transduction 
for appropriate immune responses.
MATERIALS AND METHODS
Mice. All mice used in this study were approved by the University of Dundee 
ethical review committee and maintained in compliance with UK Home 
Office Animals (Scientific Procedures) Act 1986 guidelines. PDK1flox/flox 
TamoxCre mice were generated by breeding C57BL/6GT(ROSA)26tm9(CreEsr1)Arte 
(TamoxCre), purchased from Taconic, to mice carrying PDK1 floxed alleles 
(Mora et al., 2003). HIF1flox/flox mice (Geng et al., 2006) were backcrossed 
with mice expressing cre recombinase under the control of the CD4 pro-
moter, generating HIF1flox/flox CD4Cre mice. PI3K p110D910A/D910A mice 
carry a point mutation that switches Asp910→Ala (D910A) in the p110  
subunit to inactivate catalytic activity (Okkenhaug et al., 2002). P14-LCMV 
and OTI transgenic mice have been described previously (Pircher et al., 
1989; Kurts et al., 1996).
Cell culture. CTLs were generated as described previously (Waugh et al., 
2009). In brief, lymphocytes isolated from spleens or lymph nodes of P14-
LCMV or OTI transgenic mice or nontransgenic mice were activated for 
48 h with either 100 ng/ml of soluble LCMV or OTI-specific peptide, gp33-
41 and SIINFEKL, respectively, or 0.5 µg/ml anti-CD3 antibody (2c11). Cells 
were then cultured in 20 ng/ml IL-2 (Proleukin) at 37°C for an additional 
6 d. For conditional deletion of PDK1, CTLs were prepared by activating 
PDK1flox/flox TamoxCre splenocytes with 2c11 for 2 d followed by culturing 
in IL-2 for 5 d, with 0.6 µM of 4OHT (Sigma-Aldrich) being added for the 
final 72 h of culture. Where indicated, cells were treated with various inhibi-
tors: 1 µM Akti1/2 (EMD Millipore), 20 nM rapamycin (EMD Millipore), 
10 µM IC87114 (synthesized in-house), and 10 µM LY294002 (Promega).
For short-term (20 h) TCR stimulations, naive CD8+ T cells were puri-
fied from lymph nodes of HIF1flox/flox CD4Cre and HIF1WT/WT CD4Cre 
nontransgenic mice or alternatively from P14-LCMV or OTI transgenic 
mice by magnetic cell sorting (Miltenyi Biotec). P14-LCMV and OTI naive 
CD8+ T cells were activated with gp33-41 plus 3 ng/ml anti-CD28 (clone 
37.51; eBioscience) and SIINFEKL, respectively. Nontransgenic naive CD8+ 
T cells were activated with 2c11 plus anti-CD28.
Flow cytometric analysis. Cells were labeled with APC-efluor780 CD8 
(53-6.7), FITC CD25 (7D4), APC CD44 (IM7), PE CD71 (C2), APC 
CD62L (MEL-14), Alexa Fluor 700 CD45.1 (104), and V450 Horizon 
CD45.2 (A20) purchased from eBioscience or BD. Live cells were gated 
according to their forward scatter and side scatter. Data were acquired on 
either a FACSCalibur or an LSRFortessa (BD) and analyzed using FlowJo 
software (Tree Star).
Western blot analysis and cytoplasmic nuclear fractionation. Cells 
were lysed (2 × 107/ml) in Tris lysis buffer containing 10 mM Tris, pH 7.05, 
50 mM NaCl, 30 mM Na pyrophosphate, 50 mM NaF, 5 µM ZnCl2, 10% 
glycerol, 0.5% Triton, 1 µM DTT, and protease inhibitors (Roche). Lysates 
were centrifuged (4°C, 16,000 g for 10 min) and separated by SDS-PAGE 
and transferred to nitrocellulose membrane. Blots were probed with antibodies 
recognizing pFoxo1/3aT24/34, pS6S235/236, pS6KT389, pS6KT421/S424, pAktT308, 
pAktS473, p4EBP1S37/46, and p4EBP1S65 (Cell Signaling Technology); 
pRSKS227 (Santa Cruz Biotechnology, Inc.); and unphosphorylated S6, S6K, 
Akt, and c-Myc (Cell Signaling Technology); RSK2, IB, PTEN, and 
HIF1 (Santa Cruz Biotechnology, Inc.); HIF1 (R&D Systems); PDK1 
(EMD Millipore); Glut1 (a gift from G. Holman, University of Bath, Bath, 
England, UK; Holman et al., 1990); Perforin (a gift from G. Griffith, Cam-
bridge Institute for Medical Research, Cambridge, England, UK); and Foxo1 
and Foxo3a (generated in-house). Immunoblots were probed with an SmcI 
antibody as a loading control (Bethyl Laboratories, Inc.).
To obtain cytoplasmic and nuclear fractions, cells were lysed in Hepes 
hypotonic lysis buffer (20 × 106 cells/ml; 10 mM Hepes, pH 7.9, 4 mM 
MgCl2, 15 mM KCl, 10 mM NaF, 0.1 mM EDTA, 0.15% [vol/vol] Nonidet 
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